ClinicalTrials.gg
CompletedNCT02117219Updated May 10, 2019

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

A Phase 1 interventional study of MEDI4736 Evaluate MEDI4736 in MDS and VIDAZA in Myelodysplastic Syndrome, sponsored by MedImmune LLC. Completed at 21 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-05-10.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
34th of 126
67 · median 38
Started
2014
with 3 others
Phase 1
30 of 130
4 open now
Registered
69th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 34th largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2014, is one of 30 in phase 1, and was the 69th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents

Read the detailed description

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 as monotherapy or in combination with Tremelimumab with or without Azacitidine in adult patients with myelodysplastic syndrome.

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • Myelodysplastic syndrome
  • MDS
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult male or female subjects with confirmed MDS who failed to respond, after an initial response, or were unable to tolerate hypomethylating agents, performance status of 0 - 2, and adequate organ and marrow function.

Exclusion criteria

Exclusion Criteria:

Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, prior MAb against , PD-1, or PD-L1, alllogenic or haploidentical transplant, current medication or or inflammatory disease.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    MEDI4736 Evaluate MEDI4736 in MDS

    Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS

    Biological: MEDI4736 Evaluate MEDI4736 in MDS · Drug: VIDAZA

  • Experimental
    MEDI4736 + tremelimumab

    Evaluate MEDI4736 in combination with tremelimumab

    Biological: tremelimumab

  • Experimental
    MEDI4736 + tremelimumab + azacitidine

    Evaluate MEDI4736 in combination with tremelimumab and azacitidine

    Drug: VIDAZA · Biological: tremelimumab

Interventions

  • MEDI4736 will be administered by IV infusion

    Also known as: durvalumab

  • DrugVIDAZA

    VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy

    Also known as: azacitidine

  • Biologicaltremelimumab

    tremelimumab will be administered by IV infusion

06

What researchers measure

Primary outcomes

  1. Subject's safety where no more than one out of six subjects experience DLTs at a given dose

    DLT (MEDI4736 monotherapy only) assessment will be done by reviewing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, physical examinations, and electrocardiogram (ECG) results. For monotherapy or combo w/aza AEs, SAEs, lab evaluations, vital signs, physical exams, ECGs will be done.

    Time frame: 180 days

  2. Subject's safety overall (monotherapy and combination therapies)

    Overall safety assessments will be done by reviewing adverse events (AEs, serious adverse events (SAEs), laboratory evaluations, vital signs, physical examinations and electrocardiogram (ECG) results.

    Time frame: 730 days

Secondary outcomes

  1. Clinical outcome in terms of response: duration of response

    As defined by IWG 2006 MDS response criteria

    Time frame: 2 years

  2. Clinical outcome in terms of response: transfusion requirements

    As defined by IWG 2006 MDS response criteria and incidence of transfusions.

    Time frame: 2 years

  3. Clinical outcome in terms of response: progression-free survival (PFS)

    As defined by IWG 2006 MDS response criteria

    Time frame: 2 years

  4. Clinical outcome in terms of response: survival (OS)

    As defined by IWG 2006 MDS response criteria and collection of survival data

    Time frame: 2 years

  5. Pharmacokinetics: MEDI4736 and tremelimumab concentrations in serum: peak concentration

    Peak concentration of MEDI4736 and tremelimumab in serum

    Time frame: 1 year

  6. Pharmacokinetics: MEDI4736 and tremelimumab concentrations in serum: area under the concentration-time curve

    Analysis of area under the concentration-time curve

    Time frame: 1 year

  7. Pharmacokinetics: MEDI4736 and tremelimumab concentration in serum: clearance

    Rate of MEDI4736 and tremelimumab clearance

    Time frame: 1 year

  8. Pharmacokinetics: MEDI4736 and tremelimumab concentration in serum: terminal half-life

    MEDI4736 and tremelimumab concentration terminal half-life

    Time frame: 1 year

  9. Immunogenicity

    Determine by number of subjects who develop ADA (anti-drug antibody).

    Time frame: 1 year

  10. Health-related quality of life (QOL): disease- and treatment-related symptoms (Part 1 only)

    Analysis of reporting of disease- and treatment-related symptoms (Part 1 only)

    Time frame: 2 years

  11. Health-related quality of life (QOL): pain (Part 1 only)

    Analysis of incidence of pain reporting (Part 1 only)

    Time frame: 2 years

  12. Health-related quality of life (QOL): health status (Part 1 only)

    Analysis of reporting of health status. (Part 1 only)

    Time frame: 2 years

07

Study locations

21 sites
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    New Haven, Connecticut 06520-8063, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Greenville, South Carolina 29601, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Paris Cedex 10, 75475, France
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Brighton, BN2 5BE, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Apr 2019, 59 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 59 months is above that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2014
First posted
Apr 17, 2014
StartActual
May 20, 2014
Primary completionActual
Apr 30, 2019
CompletionActual
Apr 30, 2019
Last update
May 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02117219
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Apr 17, 2014
Start date
May 20, 2014
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019
Last update
May 10, 2019

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Azacitidine · Tremelimumab

Start the discussion